(By Ed Silverman for STAT)
Cash is not always king.
In a move that should settle a highly contentious legal issue, the US Supreme Court on Monday declined to hear an appeal1 of a ruling2 that said cash payments are not the only litmus test for determining whether a patent settlement between drug makers deserves antitrust scrutiny. Continue reading article here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.